Research programme: Cdc7-ASK kinase inhibitors - Carna Biosciences/CrystalGenomics/SBI Biotech
Latest Information Update: 16 Jul 2016
At a glance
- Originator Carna Biosciences; CrystalGenomics; Ginkgo Biomedical Research Institute
- Developer Carna Biosciences; CrystalGenomics; SBI Biotech
- Mechanism of Action Cdc2 kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer